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Type 2 diabetes is an ever more common humandisease, which has as its hallmark an inability of thebody to properly maintain glucose homeostasis.
If left unchecked, it can lead to heart disease, vision loss, and
kidney disease; at this particular moment in history, it is also
important to note that this condition is correlated with a
greater risk for severe illness from COVID-19. Typically,
when a healthy person digests a meal, peptide hormone
glucagon-like peptide-1 (GLP1) is introduced into the
bloodstream and goes on to activate, in several tissues, its
cognate receptor GLP1R, initiating numerous events that
work to ensure a constant blood sugar level. Thus, when this
carefully orchestrated system breaks down, peptides related
to GLP1 serve in the clinic as injectable therapeutics
to manage the disease. The Achilles’ heel of this class of
active compounds, however, is susceptibility to cleavage by
proteases and thereby reduced half-lives in patients.
Protease sensitivity is frequently a stumbling block for the
application of peptide-based drugs. The way this looks on
the ground is that the top three clinically applied GLP1R
agonists, exenatide, liraglutide, and semaglutide, require
twice daily, once daily, and weekly injection schedules,
respectively, representing an inconvenience for patients in
the best case. Thus, the search for the holy grail of peptide
therapeutics must continue, namely, a general strategy for
modifying peptides to impart resistance to proteolysis while
enabling retention of excellent receptor agonist potency.
Or, perhaps, the search is over. In this issue of ACS Central
Science, Kumar and coauthors1 report how an N-terminal
trifluoroethyl modification fits the bill, not only in the case
of GLP1/GLP1R/DPP4, but also for other related peptides,
receptors, and proteases.
From the perspective of design, Kumar and coauthors
began with the seemingly straightforward task of imparting
protease stability to GLP1, a problem that other groups had
tackled with success in the past, albeit almost universally at
the expense of receptor agonist potency. DPP4, the greatest
stumbling block to the therapeutic success of GLP1, is
a serine protease that utilizes two active site glutamate
residues to bind the positively charged N-terminus of active
GLP1(7-37) and then hydrolytically remove the His7Ala8
dipeptide to yield inactive GLP1(9-37). The Kumar paper
cites work from 20 years ago by Flatt et al.2 and Wheeler
et al.,3 as well as a more recent patent4 and paper from
2016 by Sexton et al.,5 all of which explored various types of
N-acylation as a successful strategy to confer resistance to
DPP4 and also observed disappointing concomitant hits to
agonist activity. Operating under the hypothesis that the
acylated N-terminus may be refused by GLP1R because it
appears to the receptor to be an improperly processed agonist,
Kumar and coauthors instead opted for an N-alkylation
strategy. The authors then further explored considerations
about how N-terminal agonist modifications may impact
meaningful binding of the agonist deep within the receptor,
the belly of the beast, as the authors figuratively describe.
Here the jumping off point was the impressive cryo-EM
structure of a GLP1-GLP1R complex (PDB: 5VAI) solved
in 2017 by Skiniotis and co-workers.6 Unfortunately, though
this structure clearly reveals the manner in which the
receptor makes contact with the N-terminal His7 side chain
(namely, a cation-π interaction with R299ECL and hydrogen
bonding to W3065.36 and I3095.39), no obvious direct
contact to the N-terminus is observed to help specifically
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direct the design of the covalent modifications. Thus, an
appreciable and diverse library of 18 alkyl modifications was
designed and investigated in this work, numbered con-
sistently with the peptide prefixes used throughout the text,
which are shown in Figure 1.
Kumar and coauthors convincingly show that N-alkylation,
most thoroughly investigated in the case of the trifluoroethyl
group, of not only GLP1, but also of glucagon-like peptide-2
(GLP2), glucagon, glucose-dependent insulinotropic poly-
peptide (GIP), and the clinically administered liraglutide,
imparts protease resistance while enabling retention of agonist
potency against their cognate receptors. For example, using
HEK293 cells expressing receptors GLP1R, GIPR, GCGR,
or GLP2R corresponding to peptides GLP1, GIP, glucagon,
and GLP2, respectively, and a luciferase reporter system, it
is shown that, whereas the potency of GLP1 toward GLP1R
upon incubation with protease DPP4 drops from 3.5 to 2.8 ×
103 pM, the potency of N-trifluoroethyl-GLP1 after similar
incubation is found to remain at the very high level of 5.4 pM.
Importantly, no trans or off target activation is observed.
Excellent potencies and DPP4 resistance are shown almost
universally across the N-alkyl library, with all modified GLP1
species possessing single digit pM activation, except in
the cases of the sterically bulky biphenyl (17.6 pM) and
trifluoromethylphenyl diazirine (41.6 pM) groups, or due to
stereochemical preference (L-serine, 25.3 pM) in one case; it
is important to note that even though potency is somewhat
compromised with the latter modifications, these variants
still perform better than N-acetyl GLP1 for GLP1R activation.
The study is nicely rounded out by demonstrations of
protease stability of N-trifluoroethyl GLP1 against related
proteases DPP9 and FAP, both members of the S9B prolyl
oligopeptidase subfamily; no change in potency was observed
subsequent to incubation in the presence of these enzymes.
Finally, the results of in vivo glucose tolerance tests in mice
and serum stability assays in rats strongly support the
therapeutic utility of the N-trifluoroethyl group.
The results shown by Kumar and coauthors are very
exciting indeed from the perspective of a simple and easy to
introduce N-terminal modification, in particular N-alkylation,
which is able to broadly confer protease stability and enable
retention of agonist potency within the secretin family of
receptors and their ligands. This approach is an impressive
addition to the chemical toolbox that already houses strategies
such as cyclization, unnatural building blocks, staples,
depsipeptides, and lipidated side chains, among others.7
Although N-alkylation may not prove to be a panacea in the
field of receptor-based therapies, due to limitations that the
authors themselves point out with respect to their results
with the δ-opioid receptor, it certainly must from now on be
Figure 1. The Kumar study at a glance. (a) Prior cryo-EM structure of GLP1-GLP1R complex (PDB: 5VAI).6 (b) N-Terminal modifications
investigated. (c) Alignment of therapeutic peptides. Adapted with permission from ref 1. Copyright 2020 The Authors. Published by American
Chemical Society.
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considered when imparting protease stability is called for, at
least to exopeptidases.
Beyond this particular field, however, we feel that
N-alkylation must also be investigated with respect to myriad
other peptide properties that are key for function: transport,
trafficking, structure stabilization,8 oligomerization state, and
the likelihood of changing a peptide for injection into one that
can be orally administered, an important and growing field of
study.9 Especially considering the observation here that
receptor activation, long thought to be sacrosanct, can tolerate
such a broad variety of N-alkyl groups, such covalent
modification can be expected to impart benefits to these
other properties as well. Furthermore, not only may peptide
therapeutics be improved by N-terminal alkylation but also
peptide diagnostic tools and peptide-based biomaterials. This
must be explored, and we will wait expectantly to see into what
directions the authors’ results will take these areas of research.
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